BCL2 & HER2 Targeting Agent Updates

OncoPharm by OncoPharmPod

May 21, 202600:13:45Science & Medicine

The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma 2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved...

Related Episodes

Continue listening to more episodes from OncoPharm.

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates

Aug 27, 2026 - 00:20:26

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and comm...

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...

Kidney Cancer in a Nutshell

Aug 13, 2026 - 00:16:12

Overview of renal cell carcinoma Learning Oncology Companion:

Small Cell Lung Cancer and CINV Updates

Aug 6, 2026 - 00:17:35

This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (...

Zidesamtinib & PPIs in Pacific

Jul 30, 2026 - 00:16:32

A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesa...

Gedatolisib et al

Jul 23, 2026 - 00:18:16

This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib v...

Endurance Part 2

Jul 16, 2026 - 00:15:12

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: Le...